Browsing by Author "Bela Goyal"

Now showing 1 - 3 of 3

Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer
(Elsevier B.V., 2021) Bela Goyal; Shashi Ranjan Mani Yadav; Nikee Awasthee; Sweety Gupta; Ajaikumar B. Kunnumakkara; Subash Chandra Gupta
Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) is a widely studied lncRNA in cancer. Although dispensable for normal physiology, MALAT1 is important for cancer-related pathways regulation. It is localized in the nuclear speckles periphery along with centrally located pre-RNA splicing factors. MALAT1 associated cancer signaling pathways include MAPK/ERK, PI3K/AKT, β-catenin/Wnt, Hippo, VEGF, YAP, etc. Molecular tools such as immunoprecipitation, RNA pull-down, reporter assay, Northern blotting, microarray, and q-RT-PCR has been used to elucidate MALAT1's function in cancer pathogenesis. MALAT1 can regulate multiple steps in the development of tumours. The diagnostic and prognostic significance of MALAT1 has been demonstrated in cancers of the breast, cervix, colorectum, gallbladder, lung, ovary, pancreas, prostate, glioma, hepatocellular carcinoma, and multiple myeloma. MALAT1 has also emerged as a novel therapeutic target for solid as well as hematological malignancies. In experimental models, siRNA and antisense oligonucleotide (ASO) based strategy has been used for targeting MALAT1. The lncRNA has also been targeted for the chemosensitization and radiosensitization of cancer cells. However, most studies have been performed in preclinical models. How the cross-talk of MALAT1 with other signaling pathways affect cancer pathogenesis is the focus of this article. The diagnostic, prognostic, and therapeutic significance of MALAT1 in multiple cancer types are discussed. © 2021 Elsevier B.V.
On the Feasibility of Thallium Bromide in Long-Range Plasmonic Sensing for Enhancement of Performance
(Institute of Electrical and Electronics Engineers Inc., 2024) Virendra Kumar; Sarika Pal; Vivek Singh; Bela Goyal; Lalit Kumar Awasthi; Yogendra Kumar Prajapati
This article introduces a new plasmonic sensor utilizing long range surface plasmon resonance (LRSPR), which is constructed from a heterostructure of thallium bromide (TlBr) along with BluePhosphorene and Tungsten diselenide (BlueP/WSe2). Through meticulous analysis, we systematically investigated the optimal sensor configuration which consists of 8 nm thick silver (Ag) metal layer, a 1900 nm thick Magnesium fluoride (MgF2) dielectric buffer laye (DBL), and a 2-nm thick TlBr layer to enhance the capabilities of the sensor. The achieved configuration of he proposed sensor claims exceptional attributes, including narrower full width at half maximum (FWHM =0.01 Deg.), higher detection accuracy [DA =100 (Deg-1)], imaging figure of merit [IFOM =4410500 (Deg. RIU)-1], imaging sensitivity, (Simg. =44 105 RIU-1), and angular figure of merit (FOMang. =5814.38$ RIU-1). It exhibits significantly improved performance by achieving 38.02, 964.89, 25.39, and 61.40-times higher values of DA, IFOM, Simg., and FOMang respectively, as compared to the conventional surface plasmon resonance (CSPR) sensor. Furthermore, the penetration depth (PD) of 989.45 nm of the proposed LRSPR sensor surpasses the PD (210.01 nm) of CSPR sensors, and demonstrates precise and sensitive refractive index (RI) sensing applications in biomedical. Consequently, the proposed sensor offers superior performance over existing LRSPR sensors. © 1973-2012 IEEE.
Potential of Cytochrome P450, a Family of Xenobiotic Metabolizing Enzymes, in Cancer Therapy
(Mary Ann Liebert Inc., 2023) Ragini D. Singh; Avadhesh Avadhesh; Gaurav Sharma; Sagar Dholariya; Rima B. Shah; Bela Goyal; Subash Chandra Gupta
Significance: Targeted cancer therapy with minimal off-target consequences has shown promise for some cancer types. Although cytochrome P450 (CYP) consists of 18 families, CYP1-4 families play key role in metabolizing xenobiotics and cancer drugs. This eventually affects the process of carcinogenesis, treatment outcomes, and cancer drug resistance. Differential overexpression of CYPs in transformed cells, together with phenotypic alterations in tumors, presents a potential for therapeutic intervention. Recent Advances: Recent advances in molecular tools and information technology have helped utilize CYPs as cancer targets. The precise expression in various tumors, X-ray crystal structures, improved understanding of the structure-activity relationship, and new approaches in the development of prodrugs have supported the ongoing efforts to develop CYP-based drugs with a better therapeutic index. Critical Issues: Narrow therapeutic index, off-target effects, drug resistance, and tumor heterogeneity limit the benefits of CYP-based conventional cancer therapies. In this review, we address the CYP1-4 families as druggable targets in cancer. An emphasis is given to the CYP expression, function, and the possible mechanisms that drive expression and activity in normal and transformed tissues. The strategies that inhibit or activate CYPs for therapeutic benefits are also discussed. Future Directions: Efforts are needed to develop more selective tools that will help comprehend molecular and metabolic alterations in tumor tissues with biological end-points in relation to CYPs. This will eventually translate to developing more specific CYP inhibitors/inducers. Antioxid. Redox Signal. 38, 853-876. © Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.